{"id":"NCT04713553","sponsor":"BioNTech SE","briefTitle":"A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants","officialTitle":"A PHASE 3, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MULTIPLE PRODUCTION LOTS AND DOSE LEVELS OF THE VACCINE CANDIDATE BNT162b2 AGAINST COVID-19 IN HEALTHY PARTICIPANTS 12 THROUGH 50 YEARS OF AGE AND THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162b2 RNA-BASED COVID-19 VACCINE CANDIDATES AS A BOOSTER DOSE IN HEALTHY PARTICIPANTS 18 THROUGH 50 YEARS OF AGE","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-02-15","primaryCompletion":"2021-07-22","completion":"2021-07-22","firstPosted":"2021-01-19","resultsPosted":"2022-12-22","lastUpdate":"2022-12-22"},"enrollment":1574,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["SARS-CoV-2 Infection","COVID-19"],"interventions":[{"type":"BIOLOGICAL","name":"BNT162b2","otherNames":[]},{"type":"BIOLOGICAL","name":"BNT162b2.B.1.351","otherNames":[]}],"arms":[{"label":"Arm 1","type":"EXPERIMENTAL"},{"label":"Arm 2","type":"EXPERIMENTAL"},{"label":"Arm 3","type":"EXPERIMENTAL"},{"label":"Arm 4","type":"EXPERIMENTAL"},{"label":"Arm 5","type":"EXPERIMENTAL"},{"label":"Booster 1: BNT162b2","type":"EXPERIMENTAL"},{"label":"Booster 2: BNT162b2.B.1.351","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3, randomized, observer-blind study in healthy individuals.\n\nThe primary study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate (BNT162b2):\n\n* As a 30-microgram dose, administered from 1 of 4 manufacturing lots (batches)\n* As a 20-microgram dose, administered from 1 of the manufacturing lots\n* As a 2-dose (separated by 21 days) schedule\n* In people 12 through 50 years of age\n\nThe booster study will evaluate the safety, tolerability, and immunogenicity of 2 SARS-CoV-2 RNA vaccine candidates (BNT162b2 and BNT162b2.B.1.351):\n\n* Each as a 30-microgram dose\n* Each as a 1-dose booster vaccine, administered approximately 3 months after Dose 2\n* In people 18 through 50 years of age","primaryOutcome":{"measure":"Geometric Mean Ratios (GMRs) of Full-Length S-Binding Immunoglobulin G (IgG) Concentrations Between Individual US Lots 1, 2, and 3 at 1 Month After Dose 2: Primary Study","timeFrame":"1 Month after Dose 2","effectByArm":[{"arm":"BNT162b2 30 mcg: US Lot 1","deltaMin":6299.5,"sd":5835.4},{"arm":"BNT162b2 30 mcg: US Lot 2","deltaMin":6231.9,"sd":5763.7},{"arm":"BNT162b2 30 mcg: US Lot 3","deltaMin":6774.8,"sd":6264.9}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":14},"locations":{"siteCount":17,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=C4591017"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":351},"commonTop":["Injection site pain","Fatigue","Headache","Myalgia","Chills"]}}